CEBIOTEX leverages nanofiber engineering to create a new medical product which can be infused with multiple agents, with special usefulness for low water solubility drugs. Proprietary technology allows to produce biocompatible-biodegradable membranes (protected by several patents in EU, USA and China), and without chemical interaction between the nanofiber polymer and the agent applied. First medical need targeted is in the field of Oncology: to reduce local recurrence and spreading of tumour cells, by improving local control of cancer after surgery. First product, CEB-01, is composed by our nanofiber membrane and the chemotherapy drug SN-38. An Orphan Drug Designation (ODD) has been granted in EU for CEB-01 in Soft Tissue Sarcoma (STS). CEB-01 is placed over the surgical bed after surgeon’s removal of a tumour mass, and immediately starts delivering SN-38 locally. It’s compatible with current Standard of care, while offering a treatment option during a period of time when no other therapy can be administered (4 weeks right after surgery). First program is focused on local treatment of STS. All preclinical work has been finished, GMP certification has been granted by AEMPS (Spanish Agency of Medications and Health Products) for manufacture of CEB-01 pharmaceutical form, and we have received in January, 2020 the official approval from the AEMPS to initiate Clinical trials in patients. The trials have already started at Hospital de Sant Pau in Barcelona, showing extremely promising results. Cebiotex started its activity in 2015 as a spin-off of UPC and Hospital Sant Joan de Déu de Barcelona.